Abstract:Liposomes-based anticancer drug delivery system has been developed and widely used in clinical tumor therapy. In addition, active targeting strategies were proposed, in which antibodies or targeting ligands ware used to direct the liposomes to further encourage the interaction between drug loaded liposomes and tumors. Obviously, the density and conformation of the targeting ligand on the surface of the liposome have huge effects on its targeting efficiency in vivo. However, there is no last word about their relation or possible optimum conditions. So the purpose of this study is to establish a quantitative method to analyze the targeting ligand density on the surface of targeted liposomes, and to investigate the effect of different ligand density on the liposome distribution pattern in tumor-bearing mice. The peptide ligand-conjugated lipids were incorporated onto the liposome surface by the post incubation method. The surface-modified liposomes and free ligands ware separated by size exclusion chromatography and then the exact lipid compositions were determined using HPLC-ELSD method. The in vivo distribution of the targeted liposomes in H460 xenegraft tumor-beadng mice ware monitored using an eXplore Optix in vivo fluorescence imaging system (GE Healthcare). The images were processed and the tumor fluorescence intensities were analyzed using Kinetica 5.0 (trial version, Thermo Fisher). Liposomes containing surface 134 peptide modifications ware made by incubation with different molar ratios (2:100, 3:100, 4:100 and 5:100) of the peptide-conjugated lipids. The resulted peptide surface densities ware (0.764± 0.047)%, (0.935±0.069)%, (1.298±0.093)% and (1.594±0.028)%. After tail vein injection, the fluorescence intensity in the tumor had T_(1/2) of 67.39 h, 83.38 h, 98.69 h and 104.81 h. The mean residence times were 97.20 h, 117.42 h, 142.11 h and 150.86 h. The results indicated that with the increase of ligand density on the surface of targeted liposomes, the AUC, T_(1/2), and MRT of fluorescence intensities at tumor site showed a trend of increasing. When the ligand density was higher than 1.298%, the targeted liposomes had larger value of AUC, T_(1/2), and MRT than non-modified liposomes. These data suggested that the targeting ligand designed on basis of receptor-ligand recognization mechanism showed its advantages when the targeted liposomes had higher surface ligand density.

Optimizing the Modification Density of Acid Oligopeptides to Enhance the Bone-Targeting Activity of Liposomes

Stable biofunctionalization of hydroxyapatite (HA) surfaces by HA-binding/osteogenic modular peptides for inducing osteogenic differentiation of mesenchymal stem cells.

Comparative study of (Asp)7-CHOL-modified liposome prepared using pre-insertion and post-insertion methods for bone targeting in vivo.

Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation

Bone-targeting PLGA derived lipid drug delivery system ameliorates bone loss in osteoporotic ovariectomized rats

Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis

A Bone Targeting Nanoparticle Loaded Ogp to Restore Bone Homeostasis for Osteoporosis Therapy

Supramolecular assemblies of histidinylated β-cyclodextrin for enhanced oligopeptide delivery into osteoclast precursors

Preparation and Bone Targeting Effect of the Epirubicin-Oxidized Dextran-Alendronate Compound

Poly Aspartic Acid Peptide-Linked PLGA Based Nanoscale Particles: Potential for Bone-Targeting Drug Delivery Applications

Effects of chain lengths and backbone chirality on the bone-targeting ability of poly(glutamic acid)s

Oxidation-resistant Nanoliposomes Loaded with Osteogenic Peptides: Characteristics, Stability and Bioaccessibility

Selection of Bone-Targeting Peptides for Therapeutic Intervention: An In Vivo Evaluation and Comparison Study

Protection of osteogenic peptides in nanoliposomes: Stability, sustained release, bioaccessibility and influence on bioactive properties

A Novel Biocompatible, Simvastatin-Loaded, Bone-Targeting Lipid Nanocarrier for Treating Osteoporosis More Effectively

Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment

Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy

Piperazine‐derived bisphosphonate‐based ionizable lipid nanoparticles enhance mRNA delivery to the bone microenvironment

The Study of Liposome Surface Ligand Density on Its Targeting Efficiency in Vivo

Affinity targeting of therapeutic proteins to the bone surface – local delivery of sclerostin neutralizing antibody enhances efficacy

A Delivery System Specifically Approaching Bone Resorption Surfaces to Facilitate Therapeutic Modulation of Micrornas in Osteoclasts.